<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://en.wikipedia.org/wiki/Disappearing_polymorphs">Original</a>
    <h1>Disappearing Polymorphs</h1>
    
    <div id="readability-page-1" class="page"><div id="mw-content-text" lang="en" dir="ltr"><div>
<figure typeof="mw:File/Thumb"><a href="https://en.wikipedia.org/wiki/File:Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg"><img alt="labeled photographs showing the differing crystal structure of two different polymorphs" src="https://upload.wikimedia.org/wikipedia/en/thumb/7/76/Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg/220px-Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg" decoding="async" width="220" height="94" srcset="//upload.wikimedia.org/wikipedia/en/thumb/7/76/Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg/330px-Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/7/76/Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg/440px-Two_polymorphs_of_3-aminobenzenesulfonic_acid.jpg 2x" data-file-width="482" data-file-height="207"/></a><figcaption>Needles of two different polymorphs of <a href="https://en.wikipedia.org/wiki/Metanilic_acid" title="Metanilic acid">metanilic acid</a> taken under a microscope at ×20 magnification. Figure (a) shows Form II and (b) shows Form III; Form I was unable to be reproduced by researchers, an instance of a disappearing polymorph.<sup id="cite_ref-1"><a href="#cite_note-1">[1]</a></sup></figcaption></figure>
<p>In <a href="https://en.wikipedia.org/wiki/Materials_science" title="Materials science">materials science</a>, <b>disappearing polymorphs</b> (or <b>perverse polymorphism</b>) describes a phenomenon in which a seemingly stable <a href="https://en.wikipedia.org/wiki/Crystal" title="Crystal">crystal</a> structure is suddenly unable to be produced, instead transforming into a <a href="https://en.wikipedia.org/wiki/Polymorphism_(materials_science)" title="Polymorphism (materials science)">polymorph</a>, or differing crystal structure with the same <a href="https://en.wikipedia.org/wiki/Chemical_composition" title="Chemical composition">chemical composition</a>, during <a href="https://en.wikipedia.org/wiki/Nucleation" title="Nucleation">nucleation</a>.<sup id="cite_ref-Seddon_2-0"><a href="#cite_note-Seddon-2">[2]</a></sup><sup id="cite_ref-Bučar_3-0"><a href="#cite_note-Bučar-3">[3]</a></sup> Sometimes the resulting transformation is extremely hard or impractical to reverse, because the new polymorph may be more <a href="https://en.wikipedia.org/wiki/Metastability" title="Metastability">stable</a>.<sup id="cite_ref-4"><a href="#cite_note-4">[4]</a></sup> It is hypothesized that contact with a single microscopic <a href="https://en.wikipedia.org/wiki/Seed_crystal" title="Seed crystal">seed crystal</a> of the new polymorph can be enough to start a chain reaction causing the transformation of a much larger mass of material.<sup id="cite_ref-Dunitz_1995_5-0"><a href="#cite_note-Dunitz_1995-5">[5]</a></sup> Widespread contamination with such microscopic seed crystals may lead to the impression that the original polymorph has &#34;disappeared.&#34;
</p><p>This is of concern to both the <a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry" title="Pharmaceutical industry">pharmaceutical</a> and <a href="https://en.wikipedia.org/wiki/Computer_hardware_industry" title="Computer hardware industry">computer hardware</a> industry, where disappearing polymorphs can ruin the effectiveness of their products, and make it impossible to manufacture the original product if there is any contamination. There have been cases of laboratories growing crystals of a particular structure and when they try to recreate this, the original crystal structure isn&#39;t created but a new crystal structure is.<sup id="cite_ref-6"><a href="#cite_note-6">[6]</a></sup> The drug <a href="https://en.wikipedia.org/wiki/Paroxetine" title="Paroxetine">paroxetine</a> was subject to a lawsuit that hinged on such a pair of polymorphs, and multiple life-saving drugs, such as <a href="https://en.wikipedia.org/wiki/Ritonavir" title="Ritonavir">ritonavir</a>, have been recalled due to unexpected polymorphism.<sup id="cite_ref-Prenol_2004_7-0"><a href="#cite_note-Prenol_2004-7">[7]</a></sup> Although it may seem like a so-called disappearing polymorph has disappeared for good, it is believed that it is always possible in principle to reconstruct the original polymorph, though doing so may be impractically difficult.<sup id="cite_ref-Bučar_2015_8-0"><a href="#cite_note-Bučar_2015-8">[8]</a></sup>  Disappearing polymorphs are generally <a href="https://en.wikipedia.org/wiki/Metastability" title="Metastability">metastable</a> forms, that are replaced by a more stable form.<sup id="cite_ref-Bučar_3-1"><a href="#cite_note-Bučar-3">[3]</a></sup>
</p><p>It is hypothesized that &#34;unintentional seeding&#34; may also be responsible for the phenomenon in which it often becomes easier to <a href="https://en.wikipedia.org/wiki/Crystallization" title="Crystallization">crystallize</a> synthetic compounds over time.<sup id="cite_ref-Dunitz_1995_5-1"><a href="#cite_note-Dunitz_1995-5">[5]</a></sup>
</p>
<meta property="mw:PageProp/toc"/>
<h2><span id="Pharmaceutical.2C_legal.2C_and_industrial_impact"></span><span id="Pharmaceutical,_legal,_and_industrial_impact">Pharmaceutical, legal, and industrial impact</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=1" title="Edit section: Pharmaceutical, legal, and industrial impact"><span>edit</span></a><span>]</span></span></h2>
<p>Good review articles: <sup id="cite_ref-Bučar_2015_8-1"><a href="#cite_note-Bučar_2015-8">[8]</a></sup><sup id="cite_ref-Vure_2011_9-0"><a href="#cite_note-Vure_2011-9">[9]</a></sup><sup id="cite_ref-WILEY-VCH_2006_10-0"><a href="#cite_note-WILEY-VCH_2006-10">[10]</a></sup>. 
</p><p>Legally, patents on pharmaceutical molecules usually specify the molecule by the location and amplitude of peaks in its <a href="https://en.wikipedia.org/wiki/X-ray_crystallography" title="X-ray crystallography">X-ray diffraction spectrum</a>, <a href="https://en.wikipedia.org/wiki/Infrared_spectroscopy" title="Infrared spectroscopy">infrared spectrum</a>, and other spectrographic data. The <a href="https://en.wikipedia.org/wiki/United_States_Pharmacopeia" title="United States Pharmacopeia">United States Pharmacopoeia</a> states that two preparations of the same molecule usually have spectra with peaks at the same locations up to ± 0.10 degree, but relative intensities may vary up to 20%.<sup id="cite_ref-Vure_2011_9-1"><a href="#cite_note-Vure_2011-9">[9]</a></sup>
</p><p>In America, the first company to develop a drug (&#34;pioneer&#34;) must demonstrate the drug is safe and effective by extensive and expensive trials. After that, there would be a period of exclusive rights to sell the drug, after which other companies (&#34;generics&#34;) can market the same drug as a generic chemical under <a href="https://en.wikipedia.org/wiki/Abbreviated_New_Drug_Application" title="Abbreviated New Drug Application">Abbreviated New Drug Application</a>. The pioneer companies often attempt to <a href="https://en.wikipedia.org/wiki/Evergreening" title="Evergreening">evergreen</a> the patent drug by many methods. One of them is to argue that the generic chemical is not actually the same drug as the patented drug, and thus must be considered new drugs, and undergo the same trials as new drugs. 
</p><p>Since the appearance of generics can decrease revenue rate of patented drugs by as much as 80%, delaying the appearance of generic competitors is very profitable.<sup id="cite_ref-WILEY-VCH_2006_10-1"><a href="#cite_note-WILEY-VCH_2006-10">[10]</a></sup>
</p>
<h2><span id="Case_studies">Case studies</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=2" title="Edit section: Case studies"><span>edit</span></a><span>]</span></span></h2>
<h3><span id="Paroxetine_hydrochloride">Paroxetine hydrochloride</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=3" title="Edit section: Paroxetine hydrochloride"><span>edit</span></a><span>]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Paroxetine" title="Paroxetine">Paroxetine hydrochloride</a> was developed in the 1970s by scientists in <a href="https://en.wikipedia.org/wiki/Novo_Nordisk" title="Novo Nordisk">Ferrosan</a>, and patented as US4007196A in 1976.<sup id="cite_ref-11"><a href="#cite_note-11">[11]</a></sup> Ferrosan licensed this  patent to the <a href="https://en.wikipedia.org/wiki/Beecham_Group" title="Beecham Group">Beecham Group</a>, which later merged into <a href="https://en.wikipedia.org/wiki/GSK_plc" title="GSK plc">GSK</a> (GlaxoSmithKline at the time).
</p><p>The Paroxetine developed at that time was paroxetine anhydrate, which is a chalky powder that was hygroscopic. This made it difficult to handle. In late 1984, while scaling up the production of Paroxetine, a new crystal form (hemihydrate) suddenly appeared at two Beecham sites in the UK within a few weeks of each other. In the presence of water of humidity, mere contact with hemihydrate converts anhydrate into hemihydrate. 
</p><p>Alan Curzons, working for GSK, wrote down the &#34;Paroxetine Polymorphism&#34; memorandum on May 29, 1985, a memorandum vital to later litigations.<sup id="cite_ref-Abramson_2007_12-0"><a href="#cite_note-Abramson_2007-12">[12]</a></sup>
</p><p>When the patent for paroxetine anhydrate (the &#34;original&#34; polymorph) ran out, other companies wanted to make <a href="https://en.wikipedia.org/wiki/Generic_drug" title="Generic drug">generic antidepressants</a> using the chemical. The only problem was that by the time other companies began manufacturing, Earth&#39;s atmosphere was already seeded with microscopic quantities of paroxetine hemihydrate from GSK&#39;s manufacturing plants, which meant that anyone trying to manufacture the original polymorph would find it transformed into the still-patented version, which GSK refused to give manufacturing rights for. As it is illegal to manufacture or sell anyone&#39;s patented product without their permission, GSK sued the Canadian generic pharmaceutical company <a href="https://en.wikipedia.org/wiki/Apotex" title="Apotex">Apotex</a> for <a href="https://en.wikipedia.org/wiki/Patent_infringement" title="Patent infringement">patent infringement</a> by producing quantities of the newer paroxetine polymorph in their generic pills, asking for their products to be blocked from entering the market.<sup id="cite_ref-Abramson_2007_12-1"><a href="#cite_note-Abramson_2007-12">[12]</a></sup><sup id="cite_ref-Prenol_2004_7-1"><a href="#cite_note-Prenol_2004-7">[7]</a></sup> GSK eventually lost the case on a technicality in the <a href="https://en.wikipedia.org/wiki/Federal_Circuit_Court_of_Appeals" title="Federal Circuit Court of Appeals">U.S. Federal Circuit Court</a>, but many abstract legal questions were raised in the process which may not yet be fully resolved.<sup>[<i><a href="https://en.wikipedia.org/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="what were the details of the case? What questions were left unresolved? (July 2022)">clarification needed</span></a></i>]</sup>
</p><p>Later research showed that the &#34;anhydrate&#34; was in fact a nonstoichiometric hydrate that rapidly dehydrates and rehydrates. The hemihydrate form is more stable due to a higher number of hydrogen bonds.<sup id="cite_ref-13"><a href="#cite_note-13">[13]</a></sup>
</p>
<h3><span id="Paroxetine_mesylate">Paroxetine mesylate</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=4" title="Edit section: Paroxetine mesylate"><span>edit</span></a><span>]</span></span></h3>
<p>In order to avoid patent issues, some companies developed alternative salts of paroxetine. In the mid-1990s <a href="https://en.wikipedia.org/wiki/SmithKline_Beecham" title="SmithKline Beecham">SmithKline Beecham</a> (now a part of GSK) and <a href="https://en.wikipedia.org/wiki/Synthon_(company)" title="Synthon (company)">Synthon</a> independently developed paroxetine <a href="https://en.wikipedia.org/wiki/Mesylate" title="Mesylate">mesylate</a>. They obtained two separate patents. 
</p><p>Subsequently, all attempts to produce Synthon&#39;s version of paroxetine mesylate ended up with Beecham&#39;s version. There were two possibilities: either Synthon&#39;s version is a disappearing polymorph, or Synthon&#39;s patent application contained erroneous data. Many litigations later, there was no legal consensus on which possibility was correct.<sup id="cite_ref-Bučar_3-2"><a href="#cite_note-Bučar-3">[3]</a></sup>
</p>
<h3><span id="Ritonavir">Ritonavir</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=5" title="Edit section: Ritonavir"><span>edit</span></a><span>]</span></span></h3>
<p>Released to the public in 1996, <a href="https://en.wikipedia.org/wiki/Ritonavir" title="Ritonavir">ritonavir</a> is an <a href="https://en.wikipedia.org/wiki/Antiretroviral_medication" title="Antiretroviral medication">antiretroviral medication</a> used to help treat <a href="https://en.wikipedia.org/wiki/HIV/AIDS" title="HIV/AIDS">HIV/AIDS</a>, and has been listed on the <a href="https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">World Health Organization&#39;s List of Essential Medicines</a>.<sup id="cite_ref-WHO21st_14-0"><a href="#cite_note-WHO21st-14">[14]</a></sup> The original medication was manufactured in the form of semisolid <a href="https://en.wikipedia.org/wiki/Gel_capsule" title="Gel capsule">gel capsules</a>, based on the only known crystal form of the drug (&#34;Form I&#34;). In 1998, however, a second crystal form (&#34;Form II&#34;) was unexpectedly discovered, which had significantly lower <a href="https://en.wikipedia.org/wiki/Solubility" title="Solubility">solubility</a>, and which wasn&#39;t medically effective.<sup id="cite_ref-15"><a href="#cite_note-15">[15]</a></sup> 
</p><p>Form II was of sufficiently lower energy that it became impossible to produce Form I in any laboratory where Form II was introduced, even indirectly. Scientists who had been exposed to Form II in the past seemingly contaminated entire manufacturing plants by their presence, probably because they carried over microscopic seed crystals of the new polymorph.<sup id="cite_ref-Bučar_2015_8-2"><a href="#cite_note-Bučar_2015-8">[8]</a></sup> The drug was temporarily recalled from the market, and tens of thousands of AIDS patients went without medication for their condition, until ritonavir was reformulated, approved, and re-released to the market in 1999. It is estimated that <a href="https://en.wikipedia.org/wiki/Abbott_Laboratories" title="Abbott Laboratories">Abbott</a>, the company which produced ritonavir under the brand name <a href="https://en.wikipedia.org/wiki/Norvir" title="Norvir">Norvir</a>, lost over $250 million USD as a result of the incident.<sup id="cite_ref-Bučar_2015_8-3"><a href="#cite_note-Bučar_2015-8">[8]</a></sup>
</p><p>A later study found 3 additional morphs: a metastable polymorph, a trihydrate, and a formamide solvate.<sup id="cite_ref-16"><a href="#cite_note-16">[16]</a></sup>
</p>
<h3><span id="Rotigotine">Rotigotine</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=6" title="Edit section: Rotigotine"><span>edit</span></a><span>]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Rotigotine" title="Rotigotine">Rotigotine</a> (sold under the brand name Neupro among others) is a <a href="https://en.wikipedia.org/wiki/Dopamine_agonist" title="Dopamine agonist">dopamine agonist</a> indicated for the treatment of <a href="https://en.wikipedia.org/wiki/Parkinson%27s_disease" title="Parkinson&#39;s disease">Parkinson&#39;s disease</a> (PD) and <a href="https://en.wikipedia.org/wiki/Restless_legs_syndrome" title="Restless legs syndrome">restless legs syndrome</a> (RLS).<sup id="cite_ref-pmid19947805_17-0"><a href="#cite_note-pmid19947805-17">[17]</a></sup><sup id="cite_ref-pmid19956807_18-0"><a href="#cite_note-pmid19956807-18">[18]</a></sup> In 2007, the Neupro patch was approved by the <a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) as the first <a href="https://en.wikipedia.org/wiki/Transdermal_patch" title="Transdermal patch">transdermal patch treatment</a> of Parkinson&#39;s disease in the United States. The drug had been established in 1980, and no prior polymorphism had been observed. In 2008, a more stable polymorph unexpectedly emerged, which was described as resembling &#34;snow-like crystals&#34;.<sup id="cite_ref-Bučar_2015_8-4"><a href="#cite_note-Bučar_2015-8">[8]</a></sup> The new polymorph did not display any observable reduction in efficacy, but nonetheless, <a href="https://en.wikipedia.org/wiki/Schwarz_Pharma" title="Schwarz Pharma">Schwarz Pharma</a> recalled all Neupro patches in the United States and some in Europe. Those with remaining patches in Europe were  told to refrigerate their stock, since refrigeration seemed to reduce crystallization rates. The patch was reformulated in 2012, as per FDA recommendations, and was reintroduced in the United States without requiring refrigeration.<sup id="cite_ref-19"><a href="#cite_note-19">[19]</a></sup> 
</p>
<h3><span id="Progesterone">Progesterone</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=7" title="Edit section: Progesterone"><span>edit</span></a><span>]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Progesterone_(medication)" title="Progesterone (medication)">Progesterone</a> is a naturally occurring <a href="https://en.wikipedia.org/wiki/Steroid_hormone" title="Steroid hormone">steroid hormone</a> and is used in <a href="https://en.wikipedia.org/wiki/Hormone_replacement_therapy" title="Hormone replacement therapy">hormone therapy</a> and <a href="https://en.wikipedia.org/wiki/Oral_contraceptive_pill" title="Oral contraceptive pill">birth control pills</a>, among other applications. There are two known forms of naturally-occurring progesterone (or <i>nat</i>‐progesterone), and other synthetic polymorphs of the hormone have also been created and studied.<sup id="cite_ref-Lancaster_2007_20-0"><a href="#cite_note-Lancaster_2007-20">[20]</a></sup> Early scientists reported being able to crystallize both forms of <i>nat</i>‐progesterone, and could convert form 2 of into form 1 (which is more thermodynamically stable and melts at a different temperature). When later scientists tried to replicate the crystallization of form 2 from pure materials, they found themselves completely unable to do so. Attempts to replicate older instructions (and variations on those instructions) for crystallization of form 2 would invariably produce form 1 instead, sometimes even leading to crystals of exceptional purity—but of the wrong polymorph! Researchers have tentatively suggested that form 2 became gradually harder to produce around 1975, based on a review of production difficulties documented or alluded to in existing literature.<sup id="cite_ref-Lancaster_2007_20-1"><a href="#cite_note-Lancaster_2007-20">[20]</a></sup>
</p><p>Form 2 was eventually successfully synthesized by using <a href="https://en.wikipedia.org/wiki/Pregnenolone" title="Pregnenolone">pregnenolone</a>, a structurally similar compound, as an additive in the crystallization process.<sup id="cite_ref-Bučar_2015_8-5"><a href="#cite_note-Bučar_2015-8">[8]</a></sup> The additive seemed to overturn the <a href="https://en.wikipedia.org/wiki/Ostwald%27s_rule" title="Ostwald&#39;s rule">order of stability</a> of the polymorphs. Multiple theories were proposed for why earlier research was able to produce form 2 from &#34;pure&#34; ingredients, ranging from the possibility that the early researchers were unintentionally working with impure materials, to the possibility that seed crystals of form 1 had become more common in the atmosphere of laboratories since the 1970s.<sup id="cite_ref-Lancaster_2007_20-2"><a href="#cite_note-Lancaster_2007-20">[20]</a></sup>
</p>
<h3><span id="Beta-melibiose">Beta-melibiose</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=8" title="Edit section: Beta-melibiose"><span>edit</span></a><span>]</span></span></h3>
<p>Pfanstiehl Chemical Company in <a href="https://en.wikipedia.org/wiki/Waukegan,_IL" title="Waukegan, IL">Waukegan, IL</a> was known for isolating and purifying natural substances, including <a href="https://en.wikipedia.org/wiki/Melibiose" title="Melibiose">melibiose</a>. The final step of purifying melibiose was to crystallize it. However, one day, all new melibiose crystals appeared in a different morph. The old morph was called beta-melibiose and the new morph, alpha-melibiose. The chemists theorized that tiny traces of the alpha morph in the air or on the lab equipment could be causing this change, but they never found out where it was coming from. Ultimately, the company gave up. However, they suggested that if the process were attempted in a different location, where there was absolutely no trace of alpha morph, it might still be possible to successfully crystallize the beta morph.
</p><p>As of 1995, this issue might still exist. According to a survey of catalogs from various chemical companies including Merck, Fluka, BDH, Aldrich, and Sigma, only the alpha-melibiose is available.
</p><p>Beta-melibiose is in fact an <a href="https://en.wikipedia.org/wiki/Epimer" title="Epimer">epimer</a> of alpha-melibiose. However, since when in solution, alpha- and beta-melibiose rapidly convert to each other, this may still be productively considered a case of crystal polymorphism.<sup id="cite_ref-Dunitz_1995_5-2"><a href="#cite_note-Dunitz_1995-5">[5]</a></sup>
</p>
<h3><span id="Xylitol">Xylitol</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=9" title="Edit section: Xylitol"><span>edit</span></a><span>]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Xylitol" title="Xylitol">Xylitol</a>, a type of sugar, was first synthesized from <a href="https://en.wikipedia.org/wiki/Beech" title="Beech">beech</a> wood chips in September 1890 in the form of syrups, but no one reported its crystal forms until fifty years later. It has two different crystal morphs. One is a metastable, moisture-absorbing form that melts at 61 °C, and the other is a more stable form that melts at 94 °C. Notably, its metastable morph was prepared before the stable form.
</p><p>When the metastable form was brought into a lab where the stable form had previously been made, it changed into the stable form after a few days in the open air. The structure of the stable crystal was determined by.<sup id="cite_ref-21"><a href="#cite_note-21">[21]</a></sup> They failed to obtain the metastable form from a solution of alcohol, either at room temperature or near freezing; they kept ending up with the stable form. This seems to be because once the stable form has been made in a lab, its &#34;seeds&#34; or nuclei can disperse in air, influencing new crystals to grow the same way.<sup id="cite_ref-Dunitz_1995_5-3"><a href="#cite_note-Dunitz_1995-5">[5]</a></sup>
</p>
<h3><span id="Ranitidine">Ranitidine</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=10" title="Edit section: Ranitidine"><span>edit</span></a><span>]</span></span></h3>
<p><a href="https://en.wikipedia.org/wiki/Ranitidine" title="Ranitidine">Ranitidine</a>, a medicine for <a href="https://en.wikipedia.org/wiki/Peptic_ulcer_disease" title="Peptic ulcer disease">peptic ulcers</a> sold under the name of Zantac, was developed by <a href="https://en.wikipedia.org/wiki/Allen_%26_Hanburys" title="Allen &amp; Hanburys">Allen &amp; Hanburys</a> (then a part of <a href="https://en.wikipedia.org/wiki/GSK_plc" title="GSK plc">Glaxo Group Research</a>, now GSK), and patented in 1978 (US4128658A, Example 32<sup id="cite_ref-22"><a href="#cite_note-22">[22]</a></sup>). Originally, its crystals were all in <b>Form 1</b>, but in the batch prepared on April 15, 1980 exhibited a new <a href="https://en.wikipedia.org/wiki/Infrared_spectroscopy" title="Infrared spectroscopy">infrared spectrogram peak</a> at 1045 <span><img src="https://wikimedia.org/api/rest_v1/media/math/render/svg/566885471b0b025a1cfec8c171c7333963b34de7" aria-hidden="true" alt="{\displaystyle cm^{-1}}"/></span>, demonstrating that a new crystal appeared, designated <b>Form 2</b>. Subsequent batches produced more and more Form 2 despite using the same procedure, until Form 1 completely disappeared. The group patented Form 2 in 1985 (US4521431A <sup id="cite_ref-23"><a href="#cite_note-23">[23]</a></sup>) and 1987 (US4672133A<sup id="cite_ref-24"><a href="#cite_note-24">[24]</a></sup>).<sup id="cite_ref-25"><a href="#cite_note-25">[25]</a></sup>
</p><p>Interestingly, though it&#39;s very difficult to crystalize Form 1 in the presence of seeds of Form 2, once Form 1 crystals are obtained, they can be mixed with Form 2 crystals, and both forms would coexist indefinitely.<sup id="cite_ref-Bučar_3-3"><a href="#cite_note-Bučar-3">[3]</a></sup>
</p><p>As the 1978 patent was nearing its 1995 expiration, many generics companies attempted to develop generics using the procedure described in 1978 patent, but they all ended up with Form 2. Some generics companies (such as <a href="https://en.wikipedia.org/wiki/Teva_Canada" title="Teva Canada">Novopharm</a>) claimed that Glaxo never produced Form 1, and thus it should be the 1978 patent, not the 1985 patent, that covered Form 2. Depending on which patent applies, Form 2 could be marketed as generics either in 1995 or in 2002. Since an additional seven years of exclusive marketing is highly profitable, Glaxo fought back. There were multiple cases.
</p><p>In order to win the first Glaxo, Inc. v. Novopharm, Ltd case,<sup id="cite_ref-26"><a href="#cite_note-26">[26]</a></sup><sup id="cite_ref-27"><a href="#cite_note-27">[27]</a></sup> Glaxo successfully demonstrated that Form 1 could be produced according to the 1978 patent procedure. The organic chemist <a href="https://en.wikipedia.org/wiki/Jack_Baldwin_(chemist)" title="Jack Baldwin (chemist)">Jack Baldwin</a>, acting as a witness to Glaxo, had two of his <a href="https://en.wikipedia.org/wiki/Postdoctoral_researcher" title="Postdoctoral researcher">postdoctoral researchers</a>, for three times, produce Form 1 according to the 1978 patent procedure.<sup id="cite_ref-Bučar_2015_8-6"><a href="#cite_note-Bučar_2015-8">[8]</a></sup> Consequently, the court ruled that Form 2 is covered by the 1985 patent.
</p><p>Subsequent to losing the case, Novopharm attempted to bring Form 1 to market, so Glaxo sued them again in the second Glaxo, Inc. v. Novopharm, Ltd case. Glaxo argued that Novopharm could not market generics containing even trace amounts of Form 2. In particular, that means any generic Zantac containing an infrared spectrogram peak at 1045 <span><img src="https://wikimedia.org/api/rest_v1/media/math/render/svg/566885471b0b025a1cfec8c171c7333963b34de7" aria-hidden="true" alt="{\displaystyle cm^{-1}}"/></span> infringes their 1985 patent. However, during the prosecution of the first case, Glaxo accepted that the 1985 patent covers only products containing chemicals with a specific, 29-peak infrared (IR) spectrum. This was intended to avoid <a href="https://en.wikipedia.org/wiki/Double_patenting" title="Double patenting">double patenting</a> -- Glaxo had emphasized the unique aspects of Form 2 to distinguish it from the invention described in the 1978 patent, thus avoiding a situation where they were essentially trying to patent the same invention twice.  Since Glaxo could not establish the presence of the 29-peak spectrogram in Novopharm&#39;s product, the court ruled in favor of Novopharm.<sup id="cite_ref-Vure_2011_9-2"><a href="#cite_note-Vure_2011-9">[9]</a></sup><sup id="cite_ref-28"><a href="#cite_note-28">[28]</a></sup>
</p>
<blockquote><p>the claims at issue all identify Form 2 RHCl by reference to a 29-peak IR spectrum.. proof of infringement requires proof that the drug alleged to infringe would exhibit all of those peaks, not a single, potentially meaningless peak.</p><p>— <cite>110 F. 3d 1562 - Glaxo Inc v. Novopharm Ltd</cite></p></blockquote>
<h2><span id="In_fiction">In fiction</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=11" title="Edit section: In fiction"><span>edit</span></a><span>]</span></span></h2>
<blockquote><p>The atoms had begun to stack and lock—to freeze—in a different fashion. The liquid that was crystallizing hadn’t changed, but the crystals it was forming were, as far as industrial applications went, pure junk... The seed, which had come from God-only-knows where, taught the atoms the novel way in which to stack and lock, to crystallize, to freeze.</p></blockquote>
<p>In the 1963 novel <i><a href="https://en.wikipedia.org/wiki/Cat%27s_Cradle" title="Cat&#39;s Cradle">Cat&#39;s Cradle</a>,</i> by <a href="https://en.wikipedia.org/wiki/Kurt_Vonnegut" title="Kurt Vonnegut">Kurt Vonnegut</a>, the narrator learns about Ice-nine, an alternative structure of water that is solid at room temperature and acts as a <a href="https://en.wikipedia.org/wiki/Seed_crystal" title="Seed crystal">seed crystal</a> upon contact with ordinary liquid water, causing that liquid water to instantly freeze and transform into more ice-nine. Later in the book, a character frozen in ice-nine falls into the sea. Instantly, all the water in the world&#39;s seas, rivers, and groundwater transforms into solid ice-nine, leading to a climactic <a href="https://en.wikipedia.org/wiki/Global_catastrophic_risk" title="Global catastrophic risk">doomsday scenario</a>.<sup id="cite_ref-29"><a href="#cite_note-29">[29]</a></sup>
</p><p>Ice-nine has been described as an example of a disappearing polymorph in fiction.<sup id="cite_ref-Dunitz_1995_5-4"><a href="#cite_note-Dunitz_1995-5">[5]</a></sup><sup id="cite_ref-30"><a href="#cite_note-30">[30]</a></sup>
</p>
<h2><span id="See_also">See also</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=12" title="Edit section: See also"><span>edit</span></a><span>]</span></span></h2>
<ul><li><a href="https://en.wikipedia.org/wiki/Dynamical_system" title="Dynamical system">Dynamical system</a></li>
<li><a href="https://en.wikipedia.org/wiki/Memetics" title="Memetics">Memetics</a></li>
<li><a href="https://en.wikipedia.org/wiki/Metastability" title="Metastability">Metastability</a></li>
<li><a href="https://en.wikipedia.org/wiki/Ostwald%27s_rule" title="Ostwald&#39;s rule">Ostwald&#39;s Rule of Stages</a></li>
<li><a href="https://en.wikipedia.org/wiki/Prion" title="Prion">Prion</a></li>
<li><a href="https://en.wikipedia.org/wiki/Self-replicating_machine" title="Self-replicating machine">Self-replicating machine</a></li>
<li><a href="https://en.wikipedia.org/wiki/Self-replication" title="Self-replication">Self-replication</a></li></ul>
<h2><span id="References">References</span><span><span>[</span><a href="https://en.wikipedia.org/w/index.php?title=Disappearing_polymorphs&amp;action=edit&amp;section=13" title="Edit section: References"><span>edit</span></a><span>]</span></span></h2>
<div>
<ol>
<li id="cite_note-1"><span><b><a href="#cite_ref-1">^</a></b></span> <span><cite id="CITEREFRubin-PremingerBernstein2005">Rubin-Preminger JM, Bernstein J (2005-07-01). &#34;3-Aminobenzenesulfonic Acid: A Disappearing Polymorph&#34;. <i>Crystal Growth &amp; Design</i>. <b>5</b> (4): 1343–1349. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1021%2Fcg049680y">10.1021/cg049680y</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" href="https://www.worldcat.org/issn/1528-7483">1528-7483</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Crystal+Growth+%26+Design&amp;rft.atitle=3-Aminobenzenesulfonic+Acid%3A+A+Disappearing+Polymorph&amp;rft.volume=5&amp;rft.issue=4&amp;rft.pages=1343-1349&amp;rft.date=2005-07-01&amp;rft_id=info%3Adoi%2F10.1021%2Fcg049680y&amp;rft.issn=1528-7483&amp;rft.aulast=Rubin-Preminger&amp;rft.aufirst=JM&amp;rft.au=Bernstein%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Seddon-2"><span><b><a href="#cite_ref-Seddon_2-0">^</a></b></span> <span><cite id="CITEREFSeddonZaworotko1999">Seddon KR, Zaworotko M, eds. (1999). <i>Crystal Engineering: The Design and Application of Functional Solids</i>. Vol. 539. Springer Science &amp; Business Media. <a href="https://en.wikipedia.org/wiki/ISBN_(identifier)" title="ISBN (identifier)">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/978-0-7923-5905-0" title="Special:BookSources/978-0-7923-5905-0"><bdi>978-0-7923-5905-0</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Crystal+Engineering%3A+The+Design+and+Application+of+Functional+Solids&amp;rft.pub=Springer+Science+%26+Business+Media&amp;rft.date=1999&amp;rft.isbn=978-0-7923-5905-0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Bučar-3"><span>^ <a href="#cite_ref-Bučar_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Bučar_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Bučar_3-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Bučar_3-3"><sup><i><b>d</b></i></sup></a></span> <span><cite id="CITEREFBučarLancasterBernstein2015">Bučar DK, Lancaster RW, Bernstein J (June 2015). <a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479028">&#34;Disappearing polymorphs revisited&#34;</a>. <i>Angewandte Chemie</i>. <b>54</b> (24): 6972–6993. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1002%2Fanie.201410356">10.1002/anie.201410356</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" title="PMC (identifier)">PMC</a> <span title="Freely accessible"><a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479028">4479028</a></span>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/26031248">26031248</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Angewandte+Chemie&amp;rft.atitle=Disappearing+polymorphs+revisited&amp;rft.volume=54&amp;rft.issue=24&amp;rft.pages=6972-6993&amp;rft.date=2015-06&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4479028%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26031248&amp;rft_id=info%3Adoi%2F10.1002%2Fanie.201410356&amp;rft.aulast=Bu%C4%8Dar&amp;rft.aufirst=DK&amp;rft.au=Lancaster%2C+RW&amp;rft.au=Bernstein%2C+J&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4479028&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-4"><span><b><a href="#cite_ref-4">^</a></b></span> <span><cite id="CITEREFLowe2019">Lowe D (November 26, 2019). <a rel="nofollow" href="https://www.science.org/content/blog-post/perverse-polymorphism">&#34;Perverse Polymorphism&#34;</a>. <i>In the Pipeline</i>. American Association for the Advancement of Science. <a rel="nofollow" href="https://www.gwern.net/docs/www/www.science.org/2c0919164ede2fd1962d0163a0c6b37d22915741.html">Archived</a> from the original on July 4, 2022<span>. Retrieved <span>2022-07-04</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=In+the+Pipeline&amp;rft.atitle=Perverse+Polymorphism&amp;rft.date=2019-11-26&amp;rft.aulast=Lowe&amp;rft.aufirst=D&amp;rft_id=https%3A%2F%2Fwww.science.org%2Fcontent%2Fblog-post%2Fperverse-polymorphism&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Dunitz_1995-5"><span>^ <a href="#cite_ref-Dunitz_1995_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Dunitz_1995_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Dunitz_1995_5-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Dunitz_1995_5-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Dunitz_1995_5-4"><sup><i><b>e</b></i></sup></a></span> <span><cite id="CITEREFDunitzBernstein1995">Dunitz JD, Bernstein J (1995-04-01). &#34;Disappearing Polymorphs&#34;. <i>Accounts of Chemical Research</i>. <b>28</b> (4): 193–200. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1021%2Far00052a005">10.1021/ar00052a005</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" href="https://www.worldcat.org/issn/0001-4842">0001-4842</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Accounts+of+Chemical+Research&amp;rft.atitle=Disappearing+Polymorphs&amp;rft.volume=28&amp;rft.issue=4&amp;rft.pages=193-200&amp;rft.date=1995-04-01&amp;rft_id=info%3Adoi%2F10.1021%2Far00052a005&amp;rft.issn=0001-4842&amp;rft.aulast=Dunitz&amp;rft.aufirst=JD&amp;rft.au=Bernstein%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-6"><span><b><a href="#cite_ref-6">^</a></b></span> <span><cite id="CITEREFSurovVasilevChurakovStroh2019">Surov AO, Vasilev NA, Churakov AV, Stroh J, Emmerling F, Perlovich GL (2019). &#34;Solid Forms of Ciprofloxacin Salicylate: Polymorphism, Formation Pathways and Thermodynamic Stability&#34;. <i>Crystal Growth &amp; Design</i>. <b>19</b> (5): 2979–2990. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1021%2Facs.cgd.9b00185">10.1021/acs.cgd.9b00185</a>. <a href="https://en.wikipedia.org/wiki/S2CID_(identifier)" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" href="https://api.semanticscholar.org/CorpusID:132854494">132854494</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Crystal+Growth+%26+Design&amp;rft.atitle=Solid+Forms+of+Ciprofloxacin+Salicylate%3A+Polymorphism%2C+Formation+Pathways+and+Thermodynamic+Stability&amp;rft.volume=19&amp;rft.issue=5&amp;rft.pages=2979-2990&amp;rft.date=2019&amp;rft_id=info%3Adoi%2F10.1021%2Facs.cgd.9b00185&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A132854494%23id-name%3DS2CID&amp;rft.aulast=Surov&amp;rft.aufirst=AO&amp;rft.au=Vasilev%2C+NA&amp;rft.au=Churakov%2C+AV&amp;rft.au=Stroh%2C+J&amp;rft.au=Emmerling%2C+F&amp;rft.au=Perlovich%2C+GL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Prenol_2004-7"><span>^ <a href="#cite_ref-Prenol_2004_7-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Prenol_2004_7-1"><sup><i><b>b</b></i></sup></a></span> <span><cite id="CITEREFPrenol2004">Prenol A (July 2004). <a rel="nofollow" href="https://archive.today/20120720200824/http://www.blakes.com/english/view_disc.asp?ID=249">&#34;Disappearing Polymorphs and Gastrointestinal Infringement&#34;</a>. <i>blakes.com</i>. Archived from <a rel="nofollow" href="http://www.blakes.com/english/view_disc.asp?ID=249">the original</a> on 20 July 2012.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=blakes.com&amp;rft.atitle=Disappearing+Polymorphs+and+Gastrointestinal+Infringement&amp;rft.date=2004-07&amp;rft.aulast=Prenol&amp;rft.aufirst=A&amp;rft_id=http%3A%2F%2Fwww.blakes.com%2Fenglish%2Fview_disc.asp%3FID%3D249&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Bučar_2015-8"><span>^ <a href="#cite_ref-Bučar_2015_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Bučar_2015_8-6"><sup><i><b>g</b></i></sup></a></span> <span><cite id="CITEREFBučarLancasterBernstein2015">Bučar DK, Lancaster RW, Bernstein J (June 2015). <a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479028">&#34;Disappearing polymorphs revisited&#34;</a>. <i>Angewandte Chemie</i>. <b>54</b> (24): 6972–6993. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1002%2Fanie.201410356">10.1002/anie.201410356</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" title="PMC (identifier)">PMC</a> <span title="Freely accessible"><a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479028">4479028</a></span>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/26031248">26031248</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Angewandte+Chemie&amp;rft.atitle=Disappearing+polymorphs+revisited&amp;rft.volume=54&amp;rft.issue=24&amp;rft.pages=6972-6993&amp;rft.date=2015-06&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4479028%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F26031248&amp;rft_id=info%3Adoi%2F10.1002%2Fanie.201410356&amp;rft.aulast=Bu%C4%8Dar&amp;rft.aufirst=DK&amp;rft.au=Lancaster%2C+RW&amp;rft.au=Bernstein%2C+J&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4479028&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Vure_2011-9"><span>^ <a href="#cite_ref-Vure_2011_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Vure_2011_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Vure_2011_9-2"><sup><i><b>c</b></i></sup></a></span> <span><cite id="CITEREFVure2011">Vure P (2011). <a rel="nofollow" href="http://www.inderscience.com/link.php?id=43875">&#34;Polymorph patents; how strong they are really?&#34;</a>. <i>International Journal of Intellectual Property Management</i>. <b>4</b> (4): 297. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1504%2FIJIPM.2011.043875">10.1504/IJIPM.2011.043875</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" href="https://www.worldcat.org/issn/1478-9647">1478-9647</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Intellectual+Property+Management&amp;rft.atitle=Polymorph+patents%3B+how+strong+they+are+really%3F&amp;rft.volume=4&amp;rft.issue=4&amp;rft.pages=297&amp;rft.date=2011&amp;rft_id=info%3Adoi%2F10.1504%2FIJIPM.2011.043875&amp;rft.issn=1478-9647&amp;rft.aulast=Vure&amp;rft.aufirst=P&amp;rft_id=http%3A%2F%2Fwww.inderscience.com%2Flink.php%3Fid%3D43875&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-WILEY-VCH_2006-10"><span>^ <a href="#cite_ref-WILEY-VCH_2006_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WILEY-VCH_2006_10-1"><sup><i><b>b</b></i></sup></a></span> <span><cite id="CITEREFHilfiker2006">Hilfiker R, ed. (2006). &#34;14. Polymorphism and Patents from a Chemist&#39;s Point of View [1]&#34;. <i>Polymorphism in the pharmaceutical industry</i>. Weinheim: WILEY-VCH. <a href="https://en.wikipedia.org/wiki/ISBN_(identifier)" title="ISBN (identifier)">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/978-3-527-31146-0" title="Special:BookSources/978-3-527-31146-0"><bdi>978-3-527-31146-0</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=14.+Polymorphism+and+Patents+from+a+Chemist%E2%80%99s+Point+of+View+%5B1%5D&amp;rft.btitle=Polymorphism+in+the+pharmaceutical+industry&amp;rft.place=Weinheim&amp;rft.pub=WILEY-VCH&amp;rft.date=2006&amp;rft.isbn=978-3-527-31146-0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-11"><span><b><a href="#cite_ref-11">^</a></b></span> <span><span id="CITEREFChristensenSquires1977"><a rel="nofollow" href="https://patents.google.com/patent/US4007196A/en">US4007196A</a>, Christensen, Jorgen Anders &amp; Squires, Richard Felt, &#34;4-Phenylpiperidine compounds&#34;, issued 1977-02-08</span><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=US4007196A&amp;rft.cc=&amp;rft.title=4-Phenylpiperidine+compounds&amp;rft.inventor=Christensen&amp;rft.date=1977-02-08"></span></span>
</li>
<li id="cite_note-Abramson_2007-12"><span>^ <a href="#cite_ref-Abramson_2007_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Abramson_2007_12-1"><sup><i><b>b</b></i></sup></a></span> <span><cite id="CITEREFAbramson2007">Abramson B (2007). <a rel="nofollow" href="https://books.google.com/books?id=DoT8hw4phQ8C&amp;dq=disappearing+polymorphs+in+%22fiction%22&amp;pg=PA107"><i>The Secret Circuit: The Little-known Court where the Rules of the Information Age Unfold</i></a>. Rowman &amp; Littlefield. pp. 93–106. <a href="https://en.wikipedia.org/wiki/ISBN_(identifier)" title="ISBN (identifier)">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/978-0-7425-5281-4" title="Special:BookSources/978-0-7425-5281-4"><bdi>978-0-7425-5281-4</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Secret+Circuit%3A+The+Little-known+Court+where+the+Rules+of+the+Information+Age+Unfold&amp;rft.pages=93-106&amp;rft.pub=Rowman+%26+Littlefield&amp;rft.date=2007&amp;rft.isbn=978-0-7425-5281-4&amp;rft.aulast=Abramson&amp;rft.aufirst=B&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DDoT8hw4phQ8C%26dq%3Ddisappearing%2Bpolymorphs%2Bin%2B%2522fiction%2522%26pg%3DPA107&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-13"><span><b><a href="#cite_ref-13">^</a></b></span> <span><cite id="CITEREFPinaPintoSousaFábián2012">Pina MF, Pinto JF, Sousa JJ, Fábián L, Zhao M, Craig DQ (December 2012). &#34;Identification and characterization of stoichiometric and nonstoichiometric hydrate forms of paroxetine HCl: reversible changes in crystal dimensions as a function of water absorption&#34;. <i>Molecular Pharmaceutics</i>. <b>9</b> (12): 3515–3525. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1021%2Fmp3003573">10.1021/mp3003573</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/23051151">23051151</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Molecular+Pharmaceutics&amp;rft.atitle=Identification+and+characterization+of+stoichiometric+and+nonstoichiometric+hydrate+forms+of+paroxetine+HCl%3A+reversible+changes+in+crystal+dimensions+as+a+function+of+water+absorption&amp;rft.volume=9&amp;rft.issue=12&amp;rft.pages=3515-3525&amp;rft.date=2012-12&amp;rft_id=info%3Adoi%2F10.1021%2Fmp3003573&amp;rft_id=info%3Apmid%2F23051151&amp;rft.aulast=Pina&amp;rft.aufirst=MF&amp;rft.au=Pinto%2C+JF&amp;rft.au=Sousa%2C+JJ&amp;rft.au=F%C3%A1bi%C3%A1n%2C+L&amp;rft.au=Zhao%2C+M&amp;rft.au=Craig%2C+DQ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-WHO21st-14"><span><b><a href="#cite_ref-WHO21st_14-0">^</a></b></span> <span><cite id="CITEREFWorld_Health_Organization2019"><a href="https://en.wikipedia.org/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. <a href="https://en.wikipedia.org/wiki/Hdl_(identifier)" title="Hdl (identifier)">hdl</a>:<span title="Freely accessible"><a rel="nofollow" href="https://hdl.handle.net/10665%2F325771">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=World+Health+Organization+model+list+of+essential+medicines%3A+21st+list+2019&amp;rft.place=Geneva&amp;rft.pub=World+Health+Organization&amp;rft.date=2019&amp;rft_id=info%3Ahdl%2F10665%2F325771&amp;rft.au=World+Health+Organization&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-15"><span><b><a href="#cite_ref-15">^</a></b></span> <span><cite><a rel="nofollow" href="https://www.science.org/content/blog-post/down-crystal-surface">&#34;Down At the Crystal Surface&#34;</a>. <i>www.science.org</i><span>. Retrieved <span>2022-07-08</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.science.org&amp;rft.atitle=Down+At+the+Crystal+Surface&amp;rft_id=https%3A%2F%2Fwww.science.org%2Fcontent%2Fblog-post%2Fdown-crystal-surface&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-16"><span><b><a href="#cite_ref-16">^</a></b></span> <span><cite id="CITEREFMorissetteSoukaseneLevinsonCima2003">Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson O (March 2003). <a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151315">&#34;Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization&#34;</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>100</b> (5): 2180–2184. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1073%2Fpnas.0437744100">10.1073/pnas.0437744100</a>. <a href="https://en.wikipedia.org/wiki/PMC_(identifier)" title="PMC (identifier)">PMC</a> <span title="Freely accessible"><a rel="nofollow" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151315">151315</a></span>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/12604798">12604798</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;rft.atitle=Elucidation+of+crystal+form+diversity+of+the+HIV+protease+inhibitor+ritonavir+by+high-throughput+crystallization&amp;rft.volume=100&amp;rft.issue=5&amp;rft.pages=2180-2184&amp;rft.date=2003-03&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC151315%23id-name%3DPMC&amp;rft_id=info%3Apmid%2F12604798&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.0437744100&amp;rft.aulast=Morissette&amp;rft.aufirst=SL&amp;rft.au=Soukasene%2C+S&amp;rft.au=Levinson%2C+D&amp;rft.au=Cima%2C+MJ&amp;rft.au=Almarsson%2C+O&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC151315&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-pmid19947805-17"><span><b><a href="#cite_ref-pmid19947805_17-0">^</a></b></span> <span><cite id="CITEREFChenSwopeDashtipourLyons2009">Chen JJ, Swope DM, Dashtipour K, Lyons KE (December 2009). &#34;Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson&#39;s disease&#34;. <i>Pharmacotherapy</i>. <b>29</b> (12): 1452–1467. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1592%2Fphco.29.12.1452">10.1592/phco.29.12.1452</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/19947805">19947805</a>. <a href="https://en.wikipedia.org/wiki/S2CID_(identifier)" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" href="https://api.semanticscholar.org/CorpusID:40466260">40466260</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=Transdermal+rotigotine%3A+a+clinically+innovative+dopamine-receptor+agonist+for+the+management+of+Parkinson%27s+disease&amp;rft.volume=29&amp;rft.issue=12&amp;rft.pages=1452-1467&amp;rft.date=2009-12&amp;rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A40466260%23id-name%3DS2CID&amp;rft_id=info%3Apmid%2F19947805&amp;rft_id=info%3Adoi%2F10.1592%2Fphco.29.12.1452&amp;rft.aulast=Chen&amp;rft.aufirst=JJ&amp;rft.au=Swope%2C+DM&amp;rft.au=Dashtipour%2C+K&amp;rft.au=Lyons%2C+KE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-pmid19956807-18"><span><b><a href="#cite_ref-pmid19956807_18-0">^</a></b></span> <span><cite id="CITEREFDavies2009">Davies S (September 2009). &#34;Rotigotine for restless legs syndrome&#34;. <i>Drugs of Today</i>. <b>45</b> (9): 663–668. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1358%2Fdot.2009.45.9.1399952">10.1358/dot.2009.45.9.1399952</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/19956807">19956807</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs+of+Today&amp;rft.atitle=Rotigotine+for+restless+legs+syndrome&amp;rft.volume=45&amp;rft.issue=9&amp;rft.pages=663-668&amp;rft.date=2009-09&amp;rft_id=info%3Adoi%2F10.1358%2Fdot.2009.45.9.1399952&amp;rft_id=info%3Apmid%2F19956807&amp;rft.aulast=Davies&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-19"><span><b><a href="#cite_ref-19">^</a></b></span> <span><cite><a rel="nofollow" href="https://web.archive.org/web/20160323100931/http://www.pdf.org/en/media_pr/release/pr_1342559027">&#34;Neupro Patch Re-launches in the US&#34;</a>. Archived from <a rel="nofollow" href="http://www.pdf.org/en/media_pr/release/pr_1342559027">the original</a> on 2016-03-23<span>. Retrieved <span>2022-07-08</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Neupro+Patch+Re-launches+in+the+US&amp;rft_id=http%3A%2F%2Fwww.pdf.org%2Fen%2Fmedia_pr%2Frelease%2Fpr_1342559027&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-Lancaster_2007-20"><span>^ <a href="#cite_ref-Lancaster_2007_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Lancaster_2007_20-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Lancaster_2007_20-2"><sup><i><b>c</b></i></sup></a></span> <span><cite id="CITEREFLancasterKaramertzanisHulmeTocher2007">Lancaster RW, Karamertzanis PG, Hulme AT, Tocher DA, Lewis TC, Price SL (December 2007). &#34;The polymorphism of progesterone: stabilization of a &#39;disappearing&#39; polymorph by co-crystallization&#34;. <i>Journal of Pharmaceutical Sciences</i>. <b>96</b> (12): 3419–3431. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1002%2Fjps.20983">10.1002/jps.20983</a>. <a href="https://en.wikipedia.org/wiki/PMID_(identifier)" title="PMID (identifier)">PMID</a> <a rel="nofollow" href="https://pubmed.ncbi.nlm.nih.gov/17621678">17621678</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pharmaceutical+Sciences&amp;rft.atitle=The+polymorphism+of+progesterone%3A+stabilization+of+a+%27disappearing%27+polymorph+by+co-crystallization&amp;rft.volume=96&amp;rft.issue=12&amp;rft.pages=3419-3431&amp;rft.date=2007-12&amp;rft_id=info%3Adoi%2F10.1002%2Fjps.20983&amp;rft_id=info%3Apmid%2F17621678&amp;rft.aulast=Lancaster&amp;rft.aufirst=RW&amp;rft.au=Karamertzanis%2C+PG&amp;rft.au=Hulme%2C+AT&amp;rft.au=Tocher%2C+DA&amp;rft.au=Lewis%2C+TC&amp;rft.au=Price%2C+SL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-21"><span><b><a href="#cite_ref-21">^</a></b></span> <span><cite id="CITEREFKimJeffrey1969">Kim HS, Jeffrey GA (1969-12-15). <a rel="nofollow" href="https://scripts.iucr.org/cgi-bin/paper?a07025">&#34;The crystal structure of xylitol&#34;</a>. <i>Acta Crystallographica Section B: Structural Crystallography and Crystal Chemistry</i>. <b>25</b> (12): 2607–2613. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1107%2FS0567740869006133">10.1107/S0567740869006133</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" href="https://www.worldcat.org/issn/0567-7408">0567-7408</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Crystallographica+Section+B%3A+Structural+Crystallography+and+Crystal+Chemistry&amp;rft.atitle=The+crystal+structure+of+xylitol&amp;rft.volume=25&amp;rft.issue=12&amp;rft.pages=2607-2613&amp;rft.date=1969-12-15&amp;rft_id=info%3Adoi%2F10.1107%2FS0567740869006133&amp;rft.issn=0567-7408&amp;rft.aulast=Kim&amp;rft.aufirst=HS&amp;rft.au=Jeffrey%2C+GA&amp;rft_id=https%3A%2F%2Fscripts.iucr.org%2Fcgi-bin%2Fpaper%3Fa07025&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-22"><span><b><a href="#cite_ref-22">^</a></b></span> <span><span id="CITEREFPriceClitherowBradshaw1978"><a rel="nofollow" href="https://patents.google.com/patent/US4128658A/en">US4128658A</a>, Price, Barry J.; Clitherow, John W. &amp; Bradshaw, John, &#34;Aminoalkyl furan derivatives&#34;, issued 1978-12-05</span><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=US4128658A&amp;rft.cc=&amp;rft.title=Aminoalkyl+furan+derivatives&amp;rft.inventor=Price&amp;rft.date=1978-12-05"></span></span>
</li>
<li id="cite_note-23"><span><b><a href="#cite_ref-23">^</a></b></span> <span><span id="CITEREFCrookes1985"><a rel="nofollow" href="https://patents.google.com/patent/US4521431A/en">US4521431A</a>, Crookes, Derek L., &#34;Aminoalkyl furan derivative&#34;, issued 1985-06-04</span><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=US4521431A&amp;rft.cc=&amp;rft.title=Aminoalkyl+furan+derivative&amp;rft.inventor=Crookes&amp;rft.date=1985-06-04"></span></span>
</li>
<li id="cite_note-24"><span><b><a href="#cite_ref-24">^</a></b></span> <span><span id="CITEREFCrookes1987"><a rel="nofollow" href="https://patents.google.com/patent/US4672133A/en">US4672133A</a>, Crookes, Derek L., &#34;Process for forming Form 2 ranitidine hydrochloride&#34;, issued 1987-06-09</span><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=US4672133A&amp;rft.cc=&amp;rft.title=Process+for+forming+Form+2+ranitidine+hydrochloride&amp;rft.inventor=Crookes&amp;rft.date=1987-06-09"></span></span>
</li>
<li id="cite_note-25"><span><b><a href="#cite_ref-25">^</a></b></span> <span><cite><a rel="nofollow" href="https://www.liebertpub.com/doi/10.1089/blr.1995.14.423">&#34;{BLR 2023} Azeotroping Process - CAFC - Glaxo - Novopharm - Ranitidine&#34;</a>. <i>Biotechnology Law Report</i>. <b>14</b> (3): 423–504. May 1995. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.1089%2Fblr.1995.14.423">10.1089/blr.1995.14.423</a>. <a href="https://en.wikipedia.org/wiki/ISSN_(identifier)" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" href="https://www.worldcat.org/issn/0730-031X">0730-031X</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Biotechnology+Law+Report&amp;rft.atitle=%7BBLR+2023%7D+Azeotroping+Process+-+CAFC+-+Glaxo+-+Novopharm+-+Ranitidine&amp;rft.volume=14&amp;rft.issue=3&amp;rft.pages=423-504&amp;rft.date=1995-05&amp;rft_id=info%3Adoi%2F10.1089%2Fblr.1995.14.423&amp;rft.issn=0730-031X&amp;rft_id=https%3A%2F%2Fwww.liebertpub.com%2Fdoi%2F10.1089%2Fblr.1995.14.423&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-26"><span><b><a href="#cite_ref-26">^</a></b></span> <span><i>Glaxo Inc. v. Novopharm Ltd.</i>, 931 F. Supp. 1280 (E.D.N.C. 1996)</span>
</li>
<li id="cite_note-27"><span><b><a href="#cite_ref-27">^</a></b></span> <span><cite><a rel="nofollow" href="https://apnews.com/article/eb031a2970f2eaf00fdc7fc6701532d6">&#34;Glaxo Wellcome Launches Appeals Vs Novopharm Zantac Ruling&#34;</a>. <i>AP NEWS</i><span>. Retrieved <span>2023-05-31</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AP+NEWS&amp;rft.atitle=Glaxo+Wellcome+Launches+Appeals+Vs+Novopharm+Zantac+Ruling&amp;rft_id=https%3A%2F%2Fapnews.com%2Farticle%2Feb031a2970f2eaf00fdc7fc6701532d6&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-28"><span><b><a href="#cite_ref-28">^</a></b></span> <span><a rel="nofollow" href="https://openjurist.org/110/f3d/1562">110 F. 3d 1562 - Glaxo Inc v. Novopharm Ltd. No. 96-1466. United States Court of Appeals, Federal Circuit. April 4, 1997.</a></span>
</li>
<li id="cite_note-29"><span><b><a href="#cite_ref-29">^</a></b></span> <span><cite id="CITEREFHicks2020">Hicks AJ (2020-05-18). &#34;Cat&#39;s Cradle&#34;. <i>Posthumanism in the Novels of Kurt Vonnegut</i>. Routledge. pp. 25–51. <a href="https://en.wikipedia.org/wiki/Doi_(identifier)" title="Doi (identifier)">doi</a>:<a rel="nofollow" href="https://doi.org/10.4324%2F9780367521646-3">10.4324/9780367521646-3</a>. <a href="https://en.wikipedia.org/wiki/ISBN_(identifier)" title="ISBN (identifier)">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/9780367521646" title="Special:BookSources/9780367521646"><bdi>9780367521646</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.atitle=Cat%27s+Cradle&amp;rft.btitle=Posthumanism+in+the+Novels+of+Kurt+Vonnegut&amp;rft.pages=25-51&amp;rft.pub=Routledge&amp;rft.date=2020-05-18&amp;rft_id=info%3Adoi%2F10.4324%2F9780367521646-3&amp;rft.isbn=9780367521646&amp;rft.aulast=Hicks&amp;rft.aufirst=AJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
<li id="cite_note-30"><span><b><a href="#cite_ref-30">^</a></b></span> <span><cite id="CITEREFAbramson2007">Abramson B (2007). <a rel="nofollow" href="https://books.google.com/books?id=DoT8hw4phQ8C&amp;dq=disappearing+polymorphs+in+%22fiction%22&amp;pg=PA107"><i>The Secret Circuit: The Little-known Court where the Rules of the Information Age Unfold</i></a>. Rowman &amp; Littlefield. p. 92. <a href="https://en.wikipedia.org/wiki/ISBN_(identifier)" title="ISBN (identifier)">ISBN</a> <a href="https://en.wikipedia.org/wiki/Special:BookSources/978-0-7425-5281-4" title="Special:BookSources/978-0-7425-5281-4"><bdi>978-0-7425-5281-4</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Secret+Circuit%3A+The+Little-known+Court+where+the+Rules+of+the+Information+Age+Unfold&amp;rft.pages=92&amp;rft.pub=Rowman+%26+Littlefield&amp;rft.date=2007&amp;rft.isbn=978-0-7425-5281-4&amp;rft.aulast=Abramson&amp;rft.aufirst=B&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DDoT8hw4phQ8C%26dq%3Ddisappearing%2Bpolymorphs%2Bin%2B%2522fiction%2522%26pg%3DPA107&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ADisappearing+polymorphs"></span></span>
</li>
</ol></div>
<!-- 
NewPP limit report
Parsed by mw2448
Cached time: 20231030105030
Cache expiry: 1814400
Reduced expiry: false
Complications: [vary‐revision‐sha1, show‐toc]
CPU time usage: 0.260 seconds
Real time usage: 0.350 seconds
Preprocessor visited node count: 3464/1000000
Post‐expand include size: 61018/2097152 bytes
Template argument size: 5071/2097152 bytes
Highest expansion depth: 14/100
Expensive parser function count: 1/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 82873/5000000 bytes
Lua time usage: 0.136/10.000 seconds
Lua memory usage: 7099249/52428800 bytes
Number of Wikibase entities loaded: 0/400
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  284.143      1 -total
 62.00%  176.156      1 Template:Reflist
 34.43%   97.821     13 Template:Cite_journal
 14.63%   41.584      1 Template:Short_description
 10.81%   30.712      1 Template:Clarification_needed
  9.17%   26.065      1 Template:Fix-span
  8.39%   23.854      2 Template:Pagetype
  7.64%   21.696      2 Template:Quote
  6.72%   19.094      6 Template:Cite_book
  6.71%   19.079      4 Template:Cite_patent
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:62448004-0!canonical and timestamp 20231030105030 and revision id 1182618523. Rendering was triggered because: page-view
 -->
</div><!--esi <esi:include src="/esitest-fa8a495983347898/content" /> -->
</div></div>
  </body>
</html>
